





# abrDN Global Dynamic Dividend Fund

## Quarterly Commentary

Three-month period ended July 31, 2024



### Fund performance



The abrDN Global Dynamic Dividend Fund returned 7.10%<sup>1</sup> on a net asset value basis for the three-month period ending 31 July 2024, underperforming the 8.09% return of its benchmark, the MSCI All Country (AC) World Net Index<sup>2</sup>. On a share-price basis, the Fund returned 9.60%.

In terms of individual stock detractors, not holding NVIDIA cost the Fund in relative terms, as the shares performed strongly over the period due to continued excitement related to artificial intelligence (AI). We are monitoring the company; however, the extremely low yield raises questions about its appropriateness for a mandate of this nature. LG Chem negatively affected our performance for the quarter. Despite reporting solid earnings, investor dissatisfaction stemmed from management's lack of a definitive strategy to capitalise on its investment in LG Energy Solutions. Moreover, even though petrochemical earnings hit a low in the fourth quarter of 2022, the anticipated recovery has been progressing more sluggishly than expected due to a prolonged destocking phase that has exceeded investors' initial forecasts. The recent addition of Nike was disappointing after a weak fourth-quarter release, which highlighted concerns about the macroeconomic environment, rising competition, and a lack of innovation.

In terms of individual stock contributors, Broadcom positively influenced our performance over the quarter. The company reported another robust quarter, largely driven by a surge in AI-related revenues. Additionally, Broadcom upgraded its revenue forecasts and declared a stock split, enhancing investor sentiment. Roche stood out as a leading performer

during the period after the announcement of promising results from a Phase I study of its primary obesity drug candidate, CT-388, acquired through Carmot, which showcased significant weight loss. This is a GIP/GLP-1 receptor agonist, a drug that helps regulate blood sugar and support weight loss. Furthermore, in May, Roche held a Diagnostics Day, during which it unveiled several upcoming products poised to contribute to the company's growth trajectory. After a period of notable underperformance, Teleperformance made a remarkable recovery this quarter, positioning itself among the top performers. At the end of April, the company had announced earnings slightly above investor expectations and reaffirmed its financial outlook.

### Cumulative and annualised total return as of July 31, 2024 (%)

	NAV	Market Price	MSCI AC World Index (Net TR)
Since inception (p.a.)	3.86	2.84	7.39
10 Years (p.a.)	8.30	7.99	8.74
5 Years (p.a.)	9.36	9.11	11.05
3 Years (p.a.)	3.34	1.62	5.75
1 Year	10.76	12.19	17.02
Year to Date	8.18	12.37	13.10
3 Months	7.18	9.68	8.09
1 month	2.45	3.23	1.61

Effective February 28, 2020, the MSCI All Country World Index (Net Dividends) replaced the MSCI All Country World Index (Gross Dividends) as the Fund's primary benchmark. The Fund is subject to investment risk, including the possible loss of principal. Returns for periods less than one year are not annualized.

<sup>1</sup> Past performance is no guarantee of future results. Investment returns and principal value will fluctuate and shares, when sold, may be worth more or less than the original cost. Current performance may be lower or higher than the performance quoted. Net asset value return data include investment management fees, custodial charges and administrative fees (such as Director and legal fees) and assumes the reinvestment of all distributions.

<sup>2</sup> The MSCI AC World Index is an unmanaged index considered representative of stock markets of developed and emerging markets.



## Market review

Global equity markets ended higher over the quarter. Given continued disinflation in recent months, the European Central Bank (ECB), the Bank of Canada and the Swiss National Bank have all started cutting interest rates. Moreover, investors are factoring in further interest-rate cuts in most regions later in 2024, except in Japan, where the central bank has begun tightening policy while still remaining accommodative. However, with inflationary pressures still present, the world's major central banks have maintained a cautious monetary policy stance. Therefore, any additional easing is now expected to occur later in the year than previously forecast. There was some market volatility in July as weak US manufacturing data raised concerns about a potential recession.

US equities ended notably higher. According to an advance estimate, US annualised GDP grew by 2.8% in the second quarter of 2024, compared with a growth rate of 1.4% in the previous three months. Meanwhile, the US Federal Reserve (Fed)'s favoured measure of inflation, the core Personal Consumption Expenditures Price Index, remained at an annual rate of 2.6% in June – still above the 2% target. As a result, the Fed kept the target range for the fed funds rate at 5.25–5.50% during the period.

European equities rose over the period. Eurozone GDP, according to a flash estimate, grew sequentially by a higher-than-expected 0.3% in the second quarter of 2024, matching the growth rate experienced in the first three months of the year. According to initial estimates, annual consumer price inflation unexpectedly rose from 2.5% in June to 2.6% in July. In response to continued disinflation in recent months, the ECB cut its main refinancing operations rate by 0.25% to 4.25% at its June meeting. French President Emmanuel Macron called for a snap general election after his centrist alliance suffered a shock defeat to Marine Le Pen's far-right National Rally in the European Parliament elections in June, leading to a sharp sell-off in French equities. However, European equities rose in July after the far-right National Rally's electoral gains were less than predicted.

UK equities ended higher. In late May, Prime Minister Rishi Sunak announced a snap UK general election for 4 July. However, the Labour Party subsequently secured a substantial majority, as anticipated. UK GDP grew by 0.3% in the first quarter of 2024 after contracting by 0.2% in the fourth quarter of 2023. Annual consumer inflation remained flat month on month at 2.0% in June, in line with the Bank of England (BoE)'s 2% target. The BoE maintained its Bank Rate at a 15-year high of 5.25% over the quarter.

## Outlook & strategy

Macroeconomic factors remain as unpredictable as ever, with investors scrutinising the latest data and trying to predict when a pivot in the direction of interest rates might occur. We now have central banks on different paths with regard to rates, with the ECB cutting them in June, the Bank of Japan raising them again in July and the Fed, for now, still on hold. Geopolitical pressures remain elevated throughout the world and, with the early start to presidential proceedings in the US, this is likely to remain the case. Recessionary concerns appear to have abated, given that economic data has so far been more positive than many expected. However, one or two weak data points could alter that picture very quickly. Our focus remains at the stock level, ensuring the portfolio is well diversified on both a regional and sectoral basis, and robust enough to preserve capital in periods of market weakness.



## Important Information

### Past performance is no guarantee of future results.

The MSCI information may only be used for your internal use, may not be reproduced or redisseminated in any form and may not be used as a basis for or a component of any financial instruments or products or indices. None of the MSCI information is intended to constitute investment advice or a recommendation to make (or refrain from making) any kind of investment decision and may not be relied on as such. Historical data and analysis should not be taken as an indication or guarantee of any future performance analysis forecast or prediction. The MSCI information is provided on an "as is" basis and the user of this information assumes the entire risk of any use made of this information. MSCI, each of its affiliates and each other person involved in or related to compiling, computing or creating any MSCI information (collectively, the "MSCI" Parties) expressly disclaims all warranties (including without limitation, any warranties of originality, accuracy, completeness, timeliness, non-infringement, merchantability and fitness for a particular purpose) with respect to this information. Without limiting any of the foregoing, in no event shall any MSCI Party have any liability for any direct, indirect, special, incidental, punitive, consequential (including, without limitation, lost profits) or any other damages ([www.msci.com](http://www.msci.com)).

**Closed-end funds are traded on the secondary market through one of the stock exchanges. The Fund's investment return and principal value will fluctuate so that an investor's shares may be worth more or less than the original cost. Shares of closed-end funds may trade above (a premium) or below (a discount) the net asset value (NAV) of the Fund. The net asset value (NAV) is the value of an entity's assets less the value of its liabilities. The market price is the current price at which an asset can be bought or sold. There is no assurance that the Fund will achieve its investment objective. Past performance does not guarantee future results.**

Under U.S. tax rules applicable to the Fund, the amount and character of distributable income for each fiscal year can be finally determined only as of the end of the Fund's fiscal year. The Fund anticipates that sources of distributions to shareholders may include net investment income, net realized short-term capital gains, net realized long-term capital gains and return of capital. The estimated composition of the distributions may vary from time to time because the estimated composition may be impacted by future income, expenses and realized gains and losses on securities. For more detailed information related to the composition of the Fund's distributions, see [abrdnAGD.com](http://abrdnAGD.com).

Foreign securities are more volatile, harder to price and less liquid than U.S. securities. They are subject to different accounting and regulatory standards, as well as political and economic risks. These risks are enhanced in emerging markets countries. Equity stocks of small and mid-cap companies carry greater risk, and more volatility than equity stocks of larger, more established companies.

Commentary contained within this document is for informational purposes only, and is not intended as an offer or recommendation with respect to the purchase or sale of any security, option, future or other derivatives in such securities. Some of the information in this document may contain projections or other forward-looking statements regarding future events or future financial performance of countries, markets or companies. These statements are only predictions and actual events or results may differ materially. The reader must make his/ her own assessment of the relevance, accuracy and adequacy of the information contained in this document, and make such independent investigations, as he/she may consider necessary or appropriate for the purpose of such assessment.

Any opinion or estimate contained in this document is made on a general basis and is not to be relied on by the reader as advice. Neither abrdn nor any of its agents have given any consideration to nor have they made any investigation of the investment objectives, financial situation or particular need of the reader, any specific person or for any loss arising whether directly or indirectly as a result of the reader, any person or group of persons acting on any information, opinion or estimate contained in this document.

abrdn reserves the right to make changes and corrections to its opinions expressed in this document at any time, without notice.

In the United States, abrdn is the marketing name for the following affiliated, registered investment advisers: abrdn Inc., abrdn Investments Ltd., and abrdn Asia Limited.

©2024 This material is owned by abrdn or one of its affiliates. This material is the property of abrdn and the content cannot be reproduced or used in any way without our authorization.

For more information visit [abrdn.com](http://abrdn.com)

AA-270624-180088-27

**abrdn.com**

0003700653